Fig. 3
KN-93 attenuates the beneficial effects of paeoniflorin (PF) in DM mice. a PF treatment did not significantly alter CaMKII expression levels in hearts of mouse. The lower panel shows the statistical analysis results of the upper panel; GAPDH, n = 6/group. b KN-93 attenuated the PF-induced decrease in myocardial infarct size, the black arrow indicates the infarction site. c KN-93 inhibited the PF-repressed release of myocardial enzyme in serum. d KN-93 decreased the PF-induced increase in CGRP levels in serum at different time points after myocardial ischemia. e Heart function was assessed by fractional shortening and ejection fraction. f Representative images of hematoxylin and eosin (H&E, 1–3) and Masson’s trichrome staining (4–6); (1 and 4) WTDM group, (2 and 5) PF-WTDM-H group, (3 and 6) PF-WTDM-KN-93. g CGRP levels in serum pretreated with PF in mice of the two groups as indicated. PF-WTDM-KN-93 group, PF-WTDM mice were pretreated with KN-93 at 10 min prior to coronary artery ligation; n = 6 per group. (*P < 0.05, PF-WTDM-H vs. WTDM; # P < 0.05, PF-WTDM-KN-93 vs. PF-WTDM-H)